Joint Development Committee. The Parties shall form a joint development team (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Ideaya and [[Pfizer:Organization]], which shall have responsibility for coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of scientific information between the Parties with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on Study progress. Prior to any such meeting, the Ideaya Project Manager shall provide an update in writing to the [[Pfizer:Organization]] Project Manager, which update shall contain information about overall Study progress, recruitment status, interim analysis (if results are available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this ​ Certain information in this document has been excluded pursuant to Regulation S-K, Item [[Identifier]](b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Joint Development Committee. The JSC shall promptly establish a joint development committee (the “JDC”), which is subject to the supervision and oversight of the JSC, to review, discuss, coordinate and share information regarding # the Development of Licensed Products in the Territory, # the progress of the Regulatory Approvals and Regulatory Submissions for Licensed Products in the Territory, and # data generated (for which each Party has the right to reference in regulatory filings) from the other Party’s and their licensees’ ongoing and future Clinical Trials and filings for obtaining Registration Certification for medical devices for all indications for the Licensed Products. The JDC will meet with a frequency and in a manner as determined by the JSC. The JSC shall resolve any disputes that arise within the JDC within ​ days after any such matter is brought to the JSC for resolution. In no event shall the authority of the JDC exceed the authority of the JSC. Each Party shall be responsible for all of its own expenses of participating in the JDC.

Joint Development Committee. Within ​ days after the Effective Date, the Parties shall establish a joint development committee (the “Joint Development Committee” or the “JDC”), composed of ​ representatives of NPLH (if NPLH elects to participate) and ​ representatives of Everest, to coordinate the Development and Commercialization of the Compound and Licensed Products in the Licensed Field in the Territory. Each JDC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities. For the purposes of participation in the JDC, NPLH has the right but not the obligation to participate in the JDC. The JDC shall:

Joint Development Committee. Each Party hereby appoints three (3) representatives listed on [Exhibit A] to serve on a joint development committee (the “Joint Development Committee” or the “JDC”) as of the Effective Date to oversee the Development of the Product in the Field in the Territory under this Agreement. The JDC shall in particular: ​.

Joint Development Committee. Within ​ after the Effective Date, the Parties shall establish a joint development committee (the “Joint Development Committee” or “JDC”), which shall consist of ​ representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JDC. From time to time, each Party may substitute ​ of its representatives to the JDC on written notice to the other Party. ​ shall appoint ​ of its representatives to serve as a co-chairperson of the JDC, and ​ may change its appointed co-chairperson from time to time upon written notice ​. The JDC shall:

The JDC shall oversee Development of the Licensed Product in the Field in the Territory and any joint Development activities undertaken by the Parties. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Party shall designate its initial representatives on the JDC. Acorda shall appoint a person from among its representatives on the JDC to serve as the chairperson of the JDC. The chairperson shall coordinate administrative activities of the JDC, but shall not have any greater authority than any other representative on the JDC. Each Party shall be free to change its representatives on notice to the other or to send a substitute representative to any JDC meeting; provided, however, that each Party shall ensure that at all times during the existence of the JDC, its representatives on the JDC are appropriate in terms of expertise and seniority (including at least one member of senior management) for the then-current stage of Development of the Licensed Product in the Field in the Territory and have the authority to bind such Party with respect to matters within the purview of the JDC.

Joint Development Committee. Each Party hereby appoints three (3) representatives listed on [Exhibit A] to serve on a joint development committee (the “Joint Development Committee” or the “JDC”) as of the Effective Date to oversee the Development of the Product in the Field in the Territory under this Agreement. The JDC shall in particular: ​.

Joint Development Committee. The JSC shall promptly establish a joint development committee (the “JDC”), which is subject to the supervision and oversight of the JSC, to review, discuss, coordinate and share information regarding # the Development of Licensed Products in the Territory, # the progress of the Regulatory Approvals and Regulatory Submissions for Licensed Products in the Territory, and # data generated (for which each Party has the right to reference in regulatory filings) from the other Party’s and their licensees’ ongoing and future Clinical Trials and filings for obtaining Registration Certification for medical devices for all indications for the Licensed Products. The JDC will meet with a frequency and in a manner as determined by the JSC. The JSC shall resolve any disputes that arise within the JDC within ​ days after any such matter is brought to the JSC for resolution. In no event shall the authority of the JDC exceed the authority of the JSC. Each Party shall be responsible for all of its own expenses of participating in the JDC.

Joint Development Committee. As soon as practicable but no later than ​ after the Effective Date, the Parties shall establish a joint development committee (the “Joint Development Committee”) to monitor and facilitate the Development of Licensed Products in the Field in the Territory and the ROW Territory.

Joint Development Committee. The Parties shall establish a joint development committee (the “Joint Development Committee” or the “JDC”), composed of up to [ * ] of each Party that have [ * ] in the development of products similar to the Compounds and Collaboration Products, to monitor and coordinate the Development of the Compounds and Collaboration Products under the Collaboration. All JDC representatives will have sufficient authority within the applicable Party to make decisions [ * ] arising with the scope of the JDC’s responsibilities. The JDC shall in particular: